Accelerated Psychedelic Programs: Development Insights From Jama Pitman

Jama Pitman, a strategic adviser to Rose Hill Therapeutics, discussed the US Food and Drug Administration (FDA)'s priority review voucher program as applied to psychedelic therapeutics, the regulatory pathway toward approval, and clinical considerations for this emerging drug class.¹ Pitman clarified that priority review vouchers are designed to reduce FDA review timelines by creating efficiencies in the application process—such as rolling or real-time submission of application components—without altering the evidentiary standards required for approval.²

She noted that the 2 companies issued vouchers anticipated submitting their applications by the end of the current year, with a projected review period of approximately 2 months. Factoring in rescheduling requirements, she estimated that clinicians would likely gain access to these agents in late 2027 or 2028. Pitman referenced FDA draft guidance on the clinical development of psychedelic agents, expressing confidence that sponsors who followed that guidance were already positioned to meet evidentiary standards, stating that "we're already ahead of the game in terms of providing FDA the evidence that they need."

She identified the risk evaluation and mitigation strategy as an additional regulatory requirement likely to accompany approval of this drug class, and emphasized the importance of sponsors submitting that component in a form FDA could review expeditiously. Addressing clinician and public misperceptions, Pitman stressed that psychedelics for psychiatric indications would be administered once or twice in a highly controlled, supportive environment rather than as ongoing daily therapy, characterizing the drug as "really just a tool to help them rewire their brain in a way that allows them to be able to make meaning out of that work." She concluded by clarifying that recent regulatory activity regarding ibogaine authorized clinical trials under an investigational new drug application—not broad clinical use.

Ms Pitman is a strategic advisor at Rosehill Therapeutics.

References

1. Duerr HA. FDA fast-tracks psychedelic therapies for depression, PTSD, and alcohol use disorder. Psychiatric Times. April 24, 2026. https://www.psychiatrictimes.com/view/fda-fast-tracks-psychedelic-therapies-for-depression-ptsd-and-alcohol-use-disorder

2. FDA accelerates action on treatments for serious mental illness following executive order. Press release. April 24, 2026. Accessed May 11, 2026. https://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order